CN111803628B - 一种抗幽门螺杆菌复合制剂 - Google Patents
一种抗幽门螺杆菌复合制剂 Download PDFInfo
- Publication number
- CN111803628B CN111803628B CN202010723112.5A CN202010723112A CN111803628B CN 111803628 B CN111803628 B CN 111803628B CN 202010723112 A CN202010723112 A CN 202010723112A CN 111803628 B CN111803628 B CN 111803628B
- Authority
- CN
- China
- Prior art keywords
- helicobacter pylori
- ovotransferrin
- resisting
- lysozyme
- compound preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 241000590002 Helicobacter pylori Species 0.000 title abstract description 27
- 150000001875 compounds Chemical class 0.000 title abstract description 11
- 108010026206 Conalbumin Proteins 0.000 claims abstract description 28
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 22
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 22
- 102000016943 Muramidase Human genes 0.000 claims abstract description 21
- 108010014251 Muramidase Proteins 0.000 claims abstract description 21
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 21
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 21
- 229960000274 lysozyme Drugs 0.000 claims abstract description 21
- 239000004325 lysozyme Substances 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 239000002131 composite material Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 10
- 235000012041 food component Nutrition 0.000 abstract description 5
- 239000005417 food ingredient Substances 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 206010019375 Helicobacter infections Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241001619444 Wolfiporia cocos Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical group C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明公开了一种抗幽门螺杆菌复合制剂，属于医药技术领域。本发明提供了一种抗幽门螺杆菌的食品配方，主要包含抗幽门螺杆菌特异性免疫球蛋白、卵转铁蛋白、溶菌酶和其他食品配料，利用抗幽门螺杆菌特异性免疫球蛋白、卵转铁蛋白和溶菌酶的协同作用来达到较好的抑制幽门螺杆菌的预防、治疗效果。
Description
技术领域
本发明涉及一种抗幽门螺杆菌复合制剂，属于医药技术领域。
背景技术
幽门螺杆菌是一种定植于胃部的革兰氏阴性菌，据统计全球超50％的人类感染这种菌，10％左右感染者发展为慢性萎缩性胃炎、功能性消化不良和消化道溃疡，进而部分患者恶化为胃癌。慢性胃溃疡、胃癌为幽门螺杆菌感染、环境因素和遗传因素共同作用的结果，根除幽门螺杆菌被认为是胃癌一级预防措施，并且根除幽门螺杆菌可以彻底治愈绝大多数慢性、复发性消化溃疡疾病。目前主要临床治疗方法为抗生素制剂，但是抗生素应用范围有限，并且效果逐渐减弱，因为菌株会产生耐药性，而孕妇、儿童、老年人、抗生素过敏者、肝肾功能障碍患者不宜使用抗生素疗法。因此，一种理想的抗幽门螺杆菌的替代预防治疗方案是国内外研究的热点。
卵黄免疫球蛋白(IgY)是指鸡群经被动免疫产生具有特异性活性的抗体蛋白。IgY具有纯度高、特异性强、安全性高、热稳定性强且不激活补体等特性，在食品、医药及日用化工等领域具有广阔的应用前景。目前已经有大量研究表明抗幽门螺杆菌特异性IgY具有治疗幽门螺杆菌感染的效果，并且抗幽门螺杆菌特异性IgY不易产生耐药性、使用范围广、制备方法简单易行、成本低、与哺乳动物免疫球蛋白之间不会发生交叉免疫学反应，因此，抗幽门螺杆菌特异性IgY是一种理想的替代抗生素的治疗预防幽门螺杆菌手段。目前市场上含IgY的产品形式主要是片制剂或者压片糖果，活性成分单一，产品种类也较少，因此，亟需开发新型IgY食品，丰富IgY产品形式，为消费者提供更多的选择，同时产品具备更佳的抑菌效果。
鸡蛋中的卵转铁蛋白具有广谱抗菌性，对不同的革兰氏阴性菌和阳性菌都具有抗菌活性，特别是对于肠道致病菌和病毒，例如假单胞杆菌、大肠杆菌、链球菌、金黄色葡萄球菌等具有抑菌效果。溶菌酶对细菌、真菌都有一定的抑菌作用，抑菌效果根据菌的种类不同而有高低区别，单独作用时对革兰氏阳性菌抑制效果高于阴性菌，因而将溶菌酶与其他物质混用来提高溶菌酶的抑菌能力是一直以来的研究热点。
发明内容
为了解决上述问题，本发明提供了一种抗幽门螺杆菌的食品配方，主要包含抗幽门螺杆菌特异性免疫球蛋白、卵转铁蛋白、溶菌酶和其他食品配料，利用抗幽门螺杆菌特异性免疫球蛋白、卵转铁蛋白和溶菌酶的协同作用来达到较好的抑制幽门螺杆菌的预防、治疗效果。
本发明提供了一种抗幽门螺杆菌复合制剂，所述复合制剂包括抗幽门螺杆菌特异性免疫球蛋白和卵转铁蛋白。
在本发明一种实施方式中，所述复合制剂还包括溶菌酶。
在本发明一种实施方式中，所述抗幽门螺杆菌特异性免疫球蛋白、卵转铁蛋白和溶菌酶质量比为(1-6)：(1-6)：(0-5)。
本发明提供了一种抗幽门螺杆菌的药物，所述药物含有上述复合剂，还包括药物载体和/或药用辅料。
在本发明一种实施方式中，所述的药物的剂型为医学上认可的任意一种剂型。
本发明提供了一种抗幽门螺杆菌的食品或保健品，所述食品或保健品包括抗幽门螺杆菌特异性免疫球蛋白、卵转铁蛋白和溶菌酶。
在本发明一种实施方式中，所述抗幽门螺杆菌特异性免疫球蛋白、卵转铁蛋白和溶菌酶质量比为(1-6)：(1-6)：(0-5)。
在本发明一种实施方式中，所述食品或保健品中抗幽门螺杆菌特异性免疫球蛋白、卵转铁蛋白和溶菌酶总的质量百分数为10～500mg/g。
在本发明一种实施方式中，所述的抗幽门螺杆菌食品配方中，所述的抗幽门螺杆菌食品配方中还包括食品配料，所述抗幽门螺杆菌特异性免疫球蛋白、卵转铁蛋白、溶菌酶和食品配料的质量比为(1-6)：(1-6)：(0-5)：(10-80)。
在本发明一种实施方式中，所述的抗幽门螺杆菌食品配方中，其他食品配料包含起赋形、调味、缓冲、着色和保护作用的一种或多种组合配料，包括全脂奶粉、脱脂奶粉、茯苓粉、大豆蛋白粉、果蔬粉、麦芽糊精和低聚糖中的一种或多种。
在本发明一种实施方式中，所述的抗幽门螺杆菌食品配方实际以固态或液态应用到食品体系中，得到酸奶、饮料、含片、胶囊或糖果。
本发明提供了一种抗幽门螺杆菌奶片，所述奶片的制备方法为：将抗幽门螺杆菌免疫球蛋白2-12重量份、卵转铁蛋白2-12重量份、溶菌酶0-10重量份粉碎得混合粉末，将其与奶粉20～150重量份搅拌均匀后，压制成型即得抗幽门螺杆菌奶片。
本发明的有益效果：
本发明采用卵转铁蛋白和抗幽门螺杆菌特异性免疫球蛋白复配，对幽门螺杆菌的抑制率可达95％以上，其抑制效果比单独使用其中一种的效果之和要优越，具有很好的协同作用。通过本发明公开的食品配方，可以有效的预防、治疗幽门螺杆菌感染，并且不产生抗药性，适用范围广，且不易发生不良反应。
具体实施方式
以下对本发明的优选实施例进行说明，应当理解实施例是为了更好地解释本发明，不用于限制本发明。
1.生物材料
抗幽门螺杆菌特异性免疫球蛋白、卵转铁蛋白、溶菌酶来源于尤丽康(江苏)生物医药有限公司。
2.评估幽门螺杆菌的抑制效果
将被诊断患有幽门螺杆菌感染的患者随机分成50人一组，1-3组分别口服实施例1-3中一种抗幽门螺杆菌复合制剂或奶片，4-6组分别服用对比例1-4中单独的抗幽门螺杆菌、卵转铁蛋白、卵转铁—乳铁蛋白和抗生素药物，每天两次，一次一粒，持续四周，用药期间通过问诊确认患者是否有不良反应，停药两周后评估治愈情况。
实施例1：一种抗幽门螺杆菌复合制剂
一种抗幽门螺杆菌复合制剂，所述复合制剂包括抗幽门螺杆菌特异性免疫球蛋白100mg和卵转铁蛋白100mg。
实施例2：一种抗幽门螺杆菌复合制剂
一种抗幽门螺杆菌复合制剂，所述复合制剂包括100份抗幽门螺杆菌特异性免疫球蛋白100mg、卵转铁蛋白80mg和溶菌酶20mg。
实施例3：一种抗幽门螺杆菌的奶片
一种抗幽门螺杆菌的奶片，奶片包括全脂奶粉500mg、抗幽门螺杆菌特异性免疫球蛋白100mg、卵转铁蛋白60mg和溶菌酶40mg。
对比例1：抗幽门螺杆菌特异性免疫球蛋白
仅含有抗幽门螺杆菌特异性免疫球蛋白200mg。
对比例2：卵转铁蛋白
仅含有卵转铁蛋白200mg。
对比例3：一种抗幽门螺杆菌复合制剂
参照实施例1，将卵转铁蛋白替换成溶菌酶，其他条件同实施例1。
对比例4：一种抗幽门螺杆菌复合制剂
参照实施例1，将卵转铁蛋白替换成乳铁蛋白，其他条件同实施例1。
对比例5：
现有的抗生素药物奥美拉唑肠溶胶囊，每颗胶囊中含有奥美拉唑20mg。
表1产品配方
表2治疗幽门螺杆菌感染的效果
由表1和表2可知，当保持添加量总量不变的情况下，实施例1中抗幽门螺杆菌IgY和卵转铁蛋白组合后对幽门螺杆菌的抑制效果，较单独抗幽门螺杆菌IgY和单独卵转铁蛋白的效果之和更优越，说明抗幽门螺杆菌IgY和卵转铁蛋白之间在治疗幽门螺杆菌感染方面相互支持，具有协同作用。另一方面，相应地，实施例1、2和对比例3的对照结果也证明了抗幽门螺杆菌IgY与卵转铁蛋白、溶菌酶之间在抑制幽门螺杆菌方面也具有相互作用。
虽然本发明已以较佳实施例公开如上，但其并非用以限定本发明，任何熟悉此技术的人，在不脱离本发明的精神和范围内，都可做各种的改动与修饰，因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (3)
1.一种抗幽门螺杆菌复合制剂，其特征在于，所述复合制剂由100 mg抗幽门螺杆菌特异性免疫球蛋白、80 mg卵转铁蛋白和20 mg溶菌酶组成。
2.一种抗幽门螺杆菌的药物，其特征在于，所述药物包含权利要求1所述的复合制剂，还包括药物载体和/或药用辅料。
3.根据权利要求2所述的药物，其特征在于，所述的药物的剂型为医学上认可的任意一种剂型。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010723112.5A CN111803628B (zh) | 2020-07-24 | 2020-07-24 | 一种抗幽门螺杆菌复合制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010723112.5A CN111803628B (zh) | 2020-07-24 | 2020-07-24 | 一种抗幽门螺杆菌复合制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111803628A CN111803628A (zh) | 2020-10-23 |
| CN111803628B true CN111803628B (zh) | 2021-05-14 |
Family
ID=72861232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010723112.5A Active CN111803628B (zh) | 2020-07-24 | 2020-07-24 | 一种抗幽门螺杆菌复合制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111803628B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115969962A (zh) * | 2021-10-15 | 2023-04-18 | 上海高科生物工程有限公司 | 一种抑制幽门螺杆菌感染的杂合蛋白组合物及其应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1340360A (zh) * | 2000-08-31 | 2002-03-20 | 长兴艾格生物制品有限公司 | 蛋黄免疫活性蛋白复合物 |
| CN105012950A (zh) * | 2010-11-23 | 2015-11-04 | 潘瑟里克公司 | 用于在广谱、未分化或混合临床应用中治疗的组合物和方法 |
| CN105949300A (zh) * | 2016-05-23 | 2016-09-21 | 吉林厚德食品有限公司 | 一种蛋白提取和分离纯化方法 |
| CN106075436A (zh) * | 2016-07-12 | 2016-11-09 | 闫小君 | 一种不含抗生素的抗幽门螺杆菌口服制剂 |
| CN110522670A (zh) * | 2019-09-21 | 2019-12-03 | 广州市可优美科技有限公司 | 一种长效抗幽门螺杆菌牙膏 |
| CN110538318A (zh) * | 2019-09-27 | 2019-12-06 | 中合泰克(南京)生物科技有限公司 | 一种防控口腔幽门螺杆菌喷剂及其制备方法 |
-
2020
- 2020-07-24 CN CN202010723112.5A patent/CN111803628B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1340360A (zh) * | 2000-08-31 | 2002-03-20 | 长兴艾格生物制品有限公司 | 蛋黄免疫活性蛋白复合物 |
| CN105012950A (zh) * | 2010-11-23 | 2015-11-04 | 潘瑟里克公司 | 用于在广谱、未分化或混合临床应用中治疗的组合物和方法 |
| CN105949300A (zh) * | 2016-05-23 | 2016-09-21 | 吉林厚德食品有限公司 | 一种蛋白提取和分离纯化方法 |
| CN106075436A (zh) * | 2016-07-12 | 2016-11-09 | 闫小君 | 一种不含抗生素的抗幽门螺杆菌口服制剂 |
| CN110522670A (zh) * | 2019-09-21 | 2019-12-03 | 广州市可优美科技有限公司 | 一种长效抗幽门螺杆菌牙膏 |
| CN110538318A (zh) * | 2019-09-27 | 2019-12-06 | 中合泰克(南京)生物科技有限公司 | 一种防控口腔幽门螺杆菌喷剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111803628A (zh) | 2020-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5198419A (en) | Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria | |
| KR101188746B1 (ko) | 에스-알릴-엘-시스테인을 유효성분으로 포함하는 위장질환 예방 또는 치료용 조성물 | |
| JP2004517067A (ja) | 初乳基材組成物 | |
| KR100333113B1 (ko) | 헬리코박터피롤리관련위십이지장질환의치료방법 | |
| EP0568200A2 (en) | Pharmaceutical and foodstuff compositions containing transferrius and antibacteral agents for potentiating host defense activity and the treatment of infections | |
| JPH0692850A (ja) | 胃腸障害治療薬 | |
| EP0623024B1 (en) | Pharmaceutical bacteriocin compositions and their use for treating gastrointestinal disorders | |
| JP6475865B2 (ja) | Ａｄｋたんぱく質を有効成分として含むカルバペネム耐性グラム陰性菌に対する抗菌用の組成物 | |
| CN111803628B (zh) | 一种抗幽门螺杆菌复合制剂 | |
| CA2054830A1 (en) | Method for producing a new medicine for both treating and preventing peptic ulcer diseases and gastritis, and it's formulated medicines | |
| KR101915550B1 (ko) | 퀴놀린 4-온 유도체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 폐렴의 예방 또는 치료용 약학적 조성물 | |
| CN107405389A (zh) | 含有adk蛋白作为活性成分的抗菌组合物，或用于预防或治疗败血症的组合物 | |
| KR20240147646A (ko) | 케피어 유래 유산균의 배양물, 및 이를 포함하는 항균 조성물 및 기능성 식품 | |
| KR20190061899A (ko) | 포도상구균의 생육을 억제하는 한천 유래 올리고당의 용도 | |
| CN103153304B (zh) | 用于治疗幽门螺旋杆菌感染的组合物 | |
| EP0431933B1 (en) | Formulated medicines for enhancing the efficacy of betalactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria | |
| CN1105563A (zh) | 抗菌组合物 | |
| JP2000060541A (ja) | ビフィズス菌増殖促進物質と整腸物質とビフィズス菌製剤 | |
| WO2020055011A1 (ko) | 병원성 세균을 효과적으로 사멸시키는 재조합 항균 효소 LysSAP26의 용도 | |
| JPH11292788A (ja) | ピロリ菌感染防御剤 | |
| KR100375342B1 (ko) | 위장 질환 개선을 위한 천연 항균물질 조성물 | |
| JPWO2020090789A1 (ja) | エクオールを有効成分として含む腸内細菌に対する抗菌剤 | |
| KR20140035744A (ko) | 해양생물체인 미더덕 유래 펩타이드를 이용한 신규 항생 펩타이드 및 이의 용도 | |
| JPH04211613A (ja) | 経口日和見感染症防止治療用組成物 | |
| CN117064936A (zh) | 一种药物组合物及在抑菌药物制备中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |